Niek B Achten1, J Wendelien Dorigo-Zetsma2, Paul D van der Linden3, Monique van Brakel4, Frans B Plötz4. 1. Department of Paediatrics, Tergooi hospitals, Rijksstraatweg 1, 1261 AN, Blaricum, The Netherlands. niek.achten@gmail.com. 2. Department of Microbiology, Tergooi hospitals, Blaricum, The Netherlands. 3. Department of Clinical Pharmacology, Tergooi hospitals, Blaricum, The Netherlands. 4. Department of Paediatrics, Tergooi hospitals, Rijksstraatweg 1, 1261 AN, Blaricum, The Netherlands.
Abstract
Significant overtreatment with antibiotics for suspected early onset sepsis (EOS) constitutes a persisting clinical problem, generating unnecessary risks, harms, and costs for many newborns. We aimed to study feasibility and impact of a sepsis calculator to help guide antibiotic for suspected EOS in a European setting. In this single-center study, the sepsis calculator was implemented as an addition to and in accordance with existing protocols. One thousand eight hundred seventy-seven newborns ≥ 35 weeks of gestational age were prospectively evaluated; an analogous retrospective control group (n = 2076) was used for impact analysis. We found that empirical treatment with intravenous antibiotics for suspected EOS was reduced from 4.8 to 2.7% after sepsis calculator implementation (relative risk reduction 44% (95% confidence interval 21.4-59.5%)). No evidence for changes in time to treatment start, treatment duration, or proven sepsis rates was found. Adherence to sepsis calculator recommendation was 91%. CONCLUSION: Pragmatic and feasible implementation of the sepsis calculator yields a 44% reduction of empirical use of antibiotics for EOS, without signs of delay or prolongation of treatment. These findings warrant a multicenter, nation-wide, randomized study evaluating systematic use of the sepsis calculator prediction model and its effects in clinical practice outside of the USA. What is known: • Significant overtreatment with antibiotics for suspected early-onset sepsis results in unnecessary costs, risks, and harms. • Implementation of the sepsis calculator in the USA has resulted in a significant decrease in empirical antibiotic treatment, without apparent adverse events. What is new: • Implementation of the sepsis calculator in daily clinical decision-making in a Dutch teaching hospital is feasible in conjunction with existing protocols, with high adherence. • Antibiotic therapy for suspected early-onset sepsis was reduced by 44% following implementation of the calculator.
Significant overtreatment with antibiotics for suspected early onset sepsis (EOS) constitutes a persisting clinical problem, generating unnecessary risks, harms, and costs for many newborns. We aimed to study feasibility and impact of a sepsis calculator to help guide antibiotic for suspected EOS in a European setting. In this single-center study, the sepsis calculator was implemented as an addition to and in accordance with existing protocols. One thousand eight hundred seventy-seven newborns ≥ 35 weeks of gestational age were prospectively evaluated; an analogous retrospective control group (n = 2076) was used for impact analysis. We found that empirical treatment with intravenous antibiotics for suspected EOS was reduced from 4.8 to 2.7% after sepsis calculator implementation (relative risk reduction 44% (95% confidence interval 21.4-59.5%)). No evidence for changes in time to treatment start, treatment duration, or proven sepsis rates was found. Adherence to sepsis calculator recommendation was 91%. CONCLUSION: Pragmatic and feasible implementation of the sepsis calculator yields a 44% reduction of empirical use of antibiotics for EOS, without signs of delay or prolongation of treatment. These findings warrant a multicenter, nation-wide, randomized study evaluating systematic use of the sepsis calculator prediction model and its effects in clinical practice outside of the USA. What is known: • Significant overtreatment with antibiotics for suspected early-onset sepsis results in unnecessary costs, risks, and harms. • Implementation of the sepsis calculator in the USA has resulted in a significant decrease in empirical antibiotic treatment, without apparent adverse events. What is new: • Implementation of the sepsis calculator in daily clinical decision-making in a Dutch teaching hospital is feasible in conjunction with existing protocols, with high adherence. • Antibiotic therapy for suspected early-onset sepsis was reduced by 44% following implementation of the calculator.
Authors: Karel G M Moons; Andre Pascal Kengne; Diederick E Grobbee; Patrick Royston; Yvonne Vergouwe; Douglas G Altman; Mark Woodward Journal: Heart Date: 2012-03-07 Impact factor: 5.994
Authors: Gabriel J Escobar; Karen M Puopolo; Soora Wi; Benjamin J Turk; Michael W Kuzniewicz; Eileen M Walsh; Thomas B Newman; John Zupancic; Ellice Lieberman; David Draper Journal: Pediatrics Date: 2013-12-23 Impact factor: 7.124
Authors: Marleen Kerste; Jellina Corver; Martine C Sonnevelt; Monique van Brakel; Paul D van der Linden; Babette A M Braams-Lisman; Frans B Plötz Journal: J Matern Fetal Neonatal Med Date: 2016-03-07
Authors: Christian Magnus Thaulow; Dag Berild; Hege Salvesen Blix; Anne Karin Brigtsen; Tor Åge Myklebust; Beate Horsberg Eriksen Journal: Front Pediatr Date: 2019-10-24 Impact factor: 3.418
Authors: D Donà; E Barbieri; M Daverio; R Lundin; C Giaquinto; T Zaoutis; M Sharland Journal: Antimicrob Resist Infect Control Date: 2020-01-03 Impact factor: 4.887
Authors: Bo M van der Weijden; Niek B Achten; Jolita Bekhof; Esther E Evers; Mylène Berk; Arvid W A Kamps; Maarten Rijpert; Gavin W Ten Tusscher; Marlies A van Houten; Frans B Plötz Journal: Acta Paediatr Date: 2020-08-10 Impact factor: 2.299
Authors: Claus Klingenberg; René F Kornelisse; Giuseppe Buonocore; Rolf F Maier; Martin Stocker Journal: Front Pediatr Date: 2018-10-09 Impact factor: 3.418
Authors: Niek B Achten; J Wendelien Dorigo-Zetsma; Annemarie M C van Rossum; Rianne Oostenbrink; Frans B Plötz Journal: Clin Exp Pediatr Date: 2020-04-16
Authors: O R E Dongen; L M van Leeuwen; P K de Groot; K Vollebregt; I Schiering; B A Wevers; S M Euser; M A van Houten Journal: Front Pediatr Date: 2021-12-10 Impact factor: 3.418